Disposition of 8490 shares by Stephen Connelly of Equillium at 7.0842 subject to Rule 16b-3
| EQ Stock | USD 0.76 0.01 1.30% |
Slightly above 61% of Equillium's investor base is looking to short. The analysis of the overall investor sentiment regarding Equillium suggests that many traders are alarmed. Equillium's investing sentiment overview a quick insight into current market opportunities from investing in Equillium. Many technical investors use Equillium stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Equillium |
Filed transaction by Equillium Director, Officer Chief Scientific Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Equillium Fundamental Analysis
We analyze Equillium's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Equillium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Equillium based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Equillium is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Equillium Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Equillium stock to make a market-neutral strategy. Peer analysis of Equillium could also be used in its relative valuation, which is a method of valuing Equillium by comparing valuation metrics with similar companies.
Peers
Equillium Related Equities
| MNPR | Monopar Therapeutics | 16.07 | ||||
| HOWL | Werewolf Therapeutics | 6.90 | ||||
| BCAB | Bioatla | 6.45 | ||||
| LYRA | Lyra Therapeutics | 5.00 | ||||
| JSPR | Jasper Therapeutics | 4.59 | ||||
| CVKD | Cadrenal Therapeutics, | 3.20 | ||||
| CHRS | Coherus BioSciences | 2.78 | ||||
| ANTX | AN2 Therapeutics | 2.70 | ||||
| HOOK | Hookipa Pharma | 2.00 | ||||
| SABS | SAB Biotherapeutics | 1.18 | ||||
| TRVI | Trevi Therapeutics | 0.44 | ||||
| CUE | Cue Biopharma | 0.81 | ||||
| EWTX | Edgewise Therapeutics | 0.83 | ||||
| SPRO | Spero Therapeutics | 1.27 | ||||
| BOLT | Bolt Biotherapeutics | 2.08 | ||||
| IKNA | Ikena Oncology | 2.19 | ||||
| ANEB | Anebulo Pharmaceuticals | 3.33 | ||||
| KTTA | Pasithea Therapeutics | 4.92 | ||||
| QNRX | Quoin Pharmaceuticals | 13.89 |
Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.